First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation

References

• VardimanJMeloJBaccaraniMChronic myelogenous leukaemia, BCR-ABL1 positiveSwerdlowSCampoEHarrisNLWHO Classification of Tumors of Hematopoietic and Lymphoid Tissue4th edLyon, FranceInternational Agency for Research on Cancer2008
   Google Scholar
• BaikieAGCourt-BrownWMBucktonKEHarndenDGJacobsPAToughIMA possible specific chromosome abnormality in human chronic myeloid leukaemiaNature19601881165116613685929
   PubMed Web of Science ®Google Scholar
• RenRMechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemiaNat Rev Cancer2005517218315719031
   PubMed Web of Science ®Google Scholar
• DaleyGQVan EttenRABaltimoreDInduction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosomeScience19902478248302406902
   PubMed Web of Science ®Google Scholar
• PearWSMillerJPXuLEfficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrowBlood199892378037929808572
   PubMed Web of Science ®Google Scholar
• KurzrockRGuttermanJUTalpazMThe molecular genetics of Philadelphia chromosome-positive leukemiasN Engl J Med19883199909983047582
   PubMed Web of Science ®Google Scholar
• PaulMKMukhopadhyayAKTyrosine kinase – role and significance in cancerInt J Med Sci2004110111515912202
   PubMed Web of Science ®Google Scholar
• SteelmanLSPohnertSCSheltonJGFranklinRABertrandFEMcCubreyJAJAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesisLeukemia20041818921814737178
   PubMed Web of Science ®Google Scholar
• Van EttenRAMechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib eraLeuk Res200428Suppl 1S21S2815036938
   PubMed Web of Science ®Google Scholar
• PiccalugaPPPaoliniSMartinelliGTyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemiaCancer20071101178118617701954
   PubMed Web of Science ®Google Scholar
• PiccalugaPPRondoniMPaoliniSRostiGMartinelliGBaccaraniMImatinib mesylate in the treatment of hematologic malignanciesExpert Opin Biol Ther200771597161117916051
   PubMed Web of Science ®Google Scholar
• DeiningerMBuchdungerEDrukerBJThe development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood20051052640265315618470
   PubMed Web of Science ®Google Scholar
• O’BrienSGGuilhotFLarsonRAImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med2003348994100412637609
   PubMed Web of Science ®Google Scholar
• HehlmannRHeimpelHHossfeldDKRandomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupBone Marrow Transplant199617Suppl 3S21S248769695
   PubMed Web of Science ®Google Scholar
• TalpazMKantarjianHKurzrockRTrujilloJMGuttermanJUInterferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patientsAnn Intern Med19911145325382001086
   PubMed Web of Science ®Google Scholar
• HasfordJBaccaraniMHehlmannRAnseriHTuraSZuffaEInterferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alphaBlood199687538453918652857
   PubMed Web of Science ®Google Scholar
• GratwohlAHermansJGoldmanJMRisk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationLancet1998352108710929798583
   PubMed Web of Science ®Google Scholar
• EiringAMKhorashadJSMorleyKDeiningerMWAdvances in the treatment of chronic myeloid leukemiaBMC Med201199921867560
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienSGFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med20063552408241717151364
   PubMed Web of Science ®Google Scholar
• HochhausAO’BrienSGGuilhotFSix-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia2009231054106119282833
   PubMed Web of Science ®Google Scholar
• BaccaraniMCortesJPaneFChronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetJ Clin Oncol2009276041605119884523
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSJabbourEImpact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemiaJ Clin Oncol2011293173317821747082
   PubMed Web of Science ®Google Scholar
• BaccaraniMSaglioGGoldmanJEvolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood20061081809182016709930
   PubMed Web of Science ®Google Scholar
• DeiningerMO’BrienSGGuilhotFInternational Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinibBlood20091141126
   Web of Science ®Google Scholar
• de LavalladeHPunnialingamSMilojkovicDPleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesisBr J Haematol200814174574718331365
   PubMed Web of Science ®Google Scholar
• LucasCMWangLAustinGMA population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trialsLeukemia2008221963196618754023
   PubMed Web of Science ®Google Scholar
• DaubHSpechtKUllrichAStrategies to overcome resistance to targeted protein kinase inhibitorsNat Rev Drug Discov200431001101015573099
   PubMed Web of Science ®Google Scholar
• GorreMEMohammedMEllwoodKClinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplificationScience200129387688011423618
   PubMed Web of Science ®Google Scholar
• ShahNPNicollJMNagarBMultiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaCancer Cell2002211712512204532
   PubMed Web of Science ®Google Scholar
• SchindlerTBornmannWPellicenaPStructural mechanism for STI-571 inhibition of abelson tyrosine kinaseScience20002891938194210988075
   PubMed Web of Science ®Google Scholar
• WeisbergEManleyPWBreitensteinWCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell2005712914115710326
   PubMed Web of Science ®Google Scholar
• KantarjianHGilesFWunderleLNilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLN Engl J Med20063542542255116775235
   PubMed Web of Science ®Google Scholar
• RostiGPalandriFCastagnettiFNilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaBlood20091144933493819822896
   PubMed Web of Science ®Google Scholar
• CortesJEJonesDO’BrienSNilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phaseJ Clin Oncol20102839239720008621
   PubMed Web of Science ®Google Scholar
• SaglioGKimDWIssaragrisilSNilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaN Engl J Med20103622251225920525993
   PubMed Web of Science ®Google Scholar
• KantarjianHMHochhausASaglioGNilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialLancet Oncol20111284185121856226
   PubMed Web of Science ®Google Scholar
• RostiGCastagnettiFGugliottaGSecond-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phaseCrit Rev Oncol Hematol20128215917021565522
   PubMed Web of Science ®Google Scholar
• O’HareTShakespeareWCZhuXAP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceCancer Cell20091640141219878872
   PubMed Web of Science ®Google Scholar
• CortesJTalpazMBixbyDA Phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findingsBlood201011621020304810
   PubMed Web of Science ®Google Scholar
• SoveriniSColarossiSGnaniAContribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid LeukemiaClin Cancer Res2006127374737917189410
   PubMed Web of Science ®Google Scholar
• SoveriniSGnaniAColarossiSPhiladelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsBlood20091142168217119589924
   PubMed Web of Science ®Google Scholar
• HughesTSaglioGBranfordSImpact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseJ Clin Oncol2009274204421019652056
   PubMed Web of Science ®Google Scholar
• MullerMCCortesJEKimDWDasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsBlood20091144944495319779040
   PubMed Web of Science ®Google Scholar
• SimonssonBGedde-DahlTMarkevarnBA randomized Phase II study comparing imatinib and the combination of imatinib and PEGylated interferon alpha-2b in newly diagnosed non-high risk chronic myeloid leukemia (CML) patients in complete hematological remission after imatinib induction therapyBlood20091143280
   Web of Science ®Google Scholar
• BakalovaRZhelevZSpasovLNilotinib versus imatinib: molecular mechanism(s) of its better efficacyCancer4252012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• BakalovaROhbaHZhelevZAntisense inhibition of Bcr-Abl/cAbl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cellsFEBS Lett2004564738415094045
   PubMed Web of Science ®Google Scholar